<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Pregabalin, a Ca(2+) channel α(2)δ-subunit <z:chebi fb="68" ids="48706">antagonist</z:chebi> with <z:chebi fb="29" ids="35480">analgesic</z:chebi> and <z:chebi fb="0" ids="35623">antiepileptic</z:chebi> activity, reduced <z:hpo ids='HP_0002529'>neuronal loss</z:hpo> and improved functional outcome in a mouse model of focal <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Pregabalin administration (5-10mg/kg, i.p.) 30-90 min after transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>/reperfusion reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, neuronal <z:hpo ids='HP_0011420'>death</z:hpo> in the ischemic penumbra and neurological deficits at 24h post-<z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Pregabalin significantly decreased the amount of Ca(2+)/calpain-mediated α-spectrin proteolysis in the cerebral cortex measured at 6h post-<z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Together with the extensive clinical experience with pregabalin for other neurological indications, our findings suggest the potential for a therapeutic benefit of pregabalin in <z:hpo ids='HP_0001297'>stroke</z:hpo> patients </plain></SENT>
</text></document>